Compare GRWG & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRWG | CRDL |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.2M | 97.3M |
| IPO Year | N/A | N/A |
| Metric | GRWG | CRDL |
|---|---|---|
| Price | $1.47 | $1.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 522.1K | 333.1K |
| Earning Date | 03-12-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $161,356,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.82 | $0.77 |
| 52 Week High | $2.40 | $1.59 |
| Indicator | GRWG | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 53.19 |
| Support Level | $1.52 | $0.94 |
| Resistance Level | $1.64 | $1.08 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 25.00 | 59.79 |
GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.